



PRACTICE AID

Anticoagulation Strategies for Preventing Stroke and Systemic Embolism in Atrial Fibrillation¹

PeerView
Family Practice



Full abbreviations, accreditation, and disclosure information available at [PeerView.com/WQZ40](https://www.peerview.com/WQZ40)

| | Warfarin (Coumadin) | Dabigatran (Pradaxa) | Rivaroxaban (Xarelto) | Apixaban (Eliquis) | Edoxaban (Savaysa) |
|------------------------------------|---|--|--|--|--|
| Generic | Yes | No | No | No | No |
| FDA approval for NVAF | Before 1982 <i>Warfarin was first used in humans in 1954, before the FDA regulated drugs</i> | October 2010 | July 2011 | December 2012 | January 2015 |
| Populations^{2,3,a} | NVAF, VHD, mechanical valve implants | NVAF, selected VHD | NVAF, selected VHD | NVAF, selected VHD | NVAF, selected VHD |
| Drug image | | | | | |
| Available strengths | Variable | 75-mg, 110-mg, or 150-mg capsule | 2.5-mg, 10-mg, 15-mg, or 20-mg tablet | 5-mg or 2.5-mg tablet | 15-mg, 30-mg, or 60-mg tablet |
| Dosing frequency | Once daily | Twice daily | Once daily | Twice daily | Once daily |
| Onset | Slow Several days | Fast A few hours | Fast A few hours | Fast A few hours | Fast A few hours |
| Kidney function | No | Yes <i>Kidney function affects the dosage</i> | Yes <i>Kidney function affects the dosage</i> | Yes <i>Kidney function affects the dosage</i> | Yes <i>Kidney function affects the dosage</i> |
| Food effect | Yes <i>Diets high in vitamin K necessitate higher doses</i> | No | Yes <i>Rivaroxaban should be taken with evening meal or largest meal of the day</i> | No | No |
| Drug interactions | Many | Few | Few | Few | Few |
| Routine lab monitoring | Yes | No | No | No | No |
| Reversal agents | Yes <i>Vitamin K, fresh frozen plasma, prothrombin complex concentrates</i> | Yes <i>Idarucizumab</i> | Yes <i>Andexanet alfa</i> | Yes <i>Andexanet alfa</i> | Soon <i>May use prothrombin complex concentrates in emergencies</i> |

For complete information about these medications, please refer to each medication's prescribing information.

^a The 2020 ACC/AHA VHD guidelines now recommend DOACs for selected patients with VHD, including native, nonrheumatic valvular disease, contingent on CHA₂DS₂-VASc score, and bioprosthetic valves, contingent on CHA₂DS₂-VASc score and time of AF onset. 1. <https://thrombosis.org/wp-content/uploads/2021/09/NATF-ACC-Patients-Sept-2021.pdf>. 2. <https://www.accessdata.fda.gov/scripts/cder/daf/>. 3. Otto CM et al. *Circulation*. 2021;143:e72-e227